Concentra Group Holdings Parent stock
CONNYSEConcentra Group Holdings Parent, Inc., HealthcareISIN US20603L1026
69Score 69 out of 100, Neutral
Price and trend
86 / 100
Price history
+115% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 46% above it.
Since February 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 1.3% below its 52-week high. Largest decline in 2 years: 23% (August 2024 to November 2025).
Chart figures for advanced users
- SMA 50$37.71
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$29.42
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$19.23
- The lowest closing price of the last twelve months.
- Resistance$43.56
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Concentra Group Holdings Parent, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $5.44B, is number 16 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.16B (up 13.9% year on year) and earnings of $166.42M (down 0.1%).
- For fiscal 2026, analysts expect on average revenue of $2.35B (up 8.7%) and adjusted earnings per share of $1.65 (up 21.2%).
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 152 of 702 in Healthcare, median 53.
- The P/E is 25.4 (Medical (Care Facilities) median 19.6, own median of recent years 14.7).
- Our model puts fair value at $37.52, with the price 15% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 157% of earnings over the last 12 months.Fundamentals 91
Weaknesses
- High debtDebt 4.13 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 43
Its standout strengths are momentum and fundamentals, while valuation and stability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $28.86 and expensive above $53.61 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $41.75 (cash-flow model) and $33.30 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $33.99, at 7.8% it would be $42.82.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11.8% on the twelve months before. Revenue has grown solidly since 2021, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 28%, operating 15%, net 8%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 5 Nov 2026EPS reported $0.52 (expected $0.44)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.65−0.1%
- Revenue
- $2.35B+0.1%
- Earnings per share
- $1.84+0.2%
- Revenue
- $2.5B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +11.7%2026 guidance raised again: revenue of $2.325 to $2.375 billion (low end up $50 million) and EBITDA up about $20 million at the midpoint.
“With respect to our updated guidance, given the continued strength of the business, we are once again raising our 2026 guidance, including the low end of our target revenue range by $50 million, resulting in a new revenue range of $2.325 billion to $2.375 billion.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $11.35M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Concentra Group Holdings Parent
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Max Healthcare InstituteMAXHEALTH.NS $9.79B54
- PACS GroupPACS $7.62B66
- ChemedCHE $7.16B75
- Fortis HealthcareFORTIS.NS $6.1B52
- LifeStance Health GroupLFST $5.38B57
- Option Care HealthOPCH $4.75B64
- Hims & Hers HealthHIMS $4.44B35
- MedicoverMCOV-B.ST $4.01B61
ETFs that hold Concentra Group Holdings Parent
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.29% | 0.30% | €2.31B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.18% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.17% | 0.30% | €2.22B |
Show 5 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.17% | 0.30% | €4.28B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.06% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.05% | 0.35% | €8.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.5B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Jul 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.